ARE WE MISSING THE BIGGER PICTURE IN CARDIOVASCULAR DISEASE PREVENTION?
Treating the whole person vs individual risk markers.

Two major cardiovascular drug trials have recently produced disappointing (some cardiologists say shocking) results, and this has brought thoughts I've had for a long time about this complex condition right to the front of my brain.
The trials are Lp(a)HORIZON and ZEUS. Both investigated drugs designed to target specific biological markers/mechanisms believed to contribute to cardiovascular disease. In HORIZON, researchers dramatically lowered lipoprotein(a), or Lp(a), a genetically influenced lipoprotein associated with increased cardiovascular risk, and in ZEUS, researchers targeted a specific inflammatory pathway believed to contribute to cardiovascular events.
Despite successfully and significantly modifying their intended biological targets, neither trial showed a reduction in cardiovascular events. Understandably, these results have generated a lot of discussion, confusion, and disappointment among cardiovascular researchers. But I wonder whether we're overlooking a much larger lesson that I don't see being discussed by that community.
What if one of the biggest problems in cardiovascular drug trials is that we're spending too much time trying to treat individual mechanisms of disease and not nearly enough time addressing the underlying conditions that drive so many of those mechanisms simultaneously?
And what if another recent cardiovascular trial, SELECT, provides an important clue?
Three trials. Three approaches. One important question.
Cardiologist Ethan Weiss recently made an interesting observation on Twitter/X about the baseline characteristics of participants in HORIZON, ZEUS, and SELECT.
He pointed out that the HORIZON population may have been considered too well treated to demonstrate additional benefit, while the ZEUS population may have been too sick, and yet the SELECT trial, which studied semaglutide in people with overweight or obesity and established cardiovascular disease but without diabetes, showed a significant reduction in cardiovascular events.
SELECT achieved approximately a 20% relative reduction in major adverse cardiovascular events, and Weiss also noted that HORIZON and ZEUS enrolled patients based on abnormal biomarkers, whereas SELECT did not. His conclusion was that we clearly still have a lot to learn.
I agree. But also I think there's another question worth asking.
Could SELECT have succeeded, at least partly, because it influenced a much broader range of interconnected pathological processes than the other two interventions? And if so, what might that tell us about how we should approach cardiovascular prevention beyond focusing so much on the next greatest drug?
The problem with treating one branch or another of a much larger tree
Modern cardiovascular medicine has become extraordinarily sophisticated at identifying and targeting individual biological mechanisms.
We can lower LDL cholesterol.
We can dramatically lower Lp(a).
We can suppress specific inflammatory pathways.
We can influence platelet activity, coagulation, blood pressure, and numerous other processes involved in cardiovascular disease.
And many of these interventions have unquestionably saved lives. I'm an integrative lipid specialist, and I still spend a lot of my clinical time helping patients understand and appropriately manage LDL, ApoB, Lp(a), and other cardiovascular risk factors, and I would never dismiss or downplay the massive benefits of evidence-based pharmacology in this disease.
But I also think we need to recognize its limitations.
Cardiovascular disease, and especially events and deaths due to it, are rarely the consequence of one isolated pathological mechanism or another.
In the average person, it develops within a complex biological environment influenced by genetics, metabolism, immune function, vascular physiology, behavior, and decades of cumulative exposures. When we identify one abnormal pathway and develop a drug to suppress it, we may successfully modify that pathway without meaningfully changing the broader environment in which cardiovascular disease develops.
Think of it like a tree.
We identify one diseased branch and develop a highly sophisticated intervention to treat it. But what if the roots continue feeding the conditions responsible for disease throughout the tree? Sometimes, such as in the case of LDL for many people, treating that branch can produce enormous benefits.
Other times though, including in some cases of elevated LDL, treating it creates surprisingly little overall effect.
Consider obesity as an example where we're not talking about just one risk factor.
Excess body fat, particularly visceral and ectopic fat, can influence cardiovascular health through an extraordinary number of interconnected mechanisms. These include insulin resistance, chronic low-grade inflammation, elevated blood pressure, endothelial dysfunction, altered lipid metabolism, increased sympathetic nervous system activity, abnormal adipokine signaling, prothrombotic changes, and impaired glucose regulation. Obesity can also contribute to obstructive sleep apnea, which itself can worsen blood pressure, metabolic health, inflammation, and cardiovascular risk. And these processes don't operate independently. They interact, reinforce one another, and potentially create self-perpetuating cycles of dysfunction.
Now imagine developing a drug that suppresses one inflammatory pathway in someone who continues to experience many of these other disturbances. Even if the drug successfully modifies its intended target, the broader pathological environment remains, and may still have a sufficient enough effect that it allows the disease process to continue to worsen.
Now consider poor diet. Are we missing the forest for the trees?
The same reductionist thinking frequently appears in discussions about nutrition. Consider the endless arguments about red meat. Much of the debate revolves around saturated fat and its effects on LDL cholesterol. That's certainly an important consideration. But is saturated fat the only potentially relevant cardiovascular effect of eating red meat?
Definitely not.
Depending on the type of meat, preparation method, overall dietary pattern, and individual biology, there are a host of other potentially important considerations.
Heme iron may influence oxidative processes.
Gut microbial metabolism of certain dietary constituents can influence TMAO production, although the clinical significance and causal contribution of TMAO remain under investigation.
Processed meats may contain substantial sodium, nitrites, and other compounds relevant to cardiovascular health.
High-temperature cooking can produce additional potentially harmful compounds.
And perhaps most importantly, we need to consider what people are eating instead of the meat.
Replacing red meat with beans, lentils, intact whole grains, vegetables, and other fiber-rich plant foods changes far more than saturated fat intake.
It can change dietary fiber, potassium, phytochemical exposure, caloric density, gut microbial activity, lipid metabolism, and numerous other factors.
So, the same dietary change may influence several biological systems at once.
Yet we frequently see researchers and commentators attempt to reduce the cardiovascular implications of an entire dietary pattern to one nutrient, one biomarker, or one proposed mechanism.
Smoking, exercise, sleep, and stress tell the same story.
Now consider cigarette smoking. Smoking doesn't simply increase one inflammatory marker or damage one component of the vascular system. It can promote oxidative stress, endothelial dysfunction, platelet activation, thrombosis, vascular inflammation, and numerous other pathological processes. Stopping smoking addresses the exposure driving many of these processes simultaneously.
Now consider physical activity. Regular exercise can improve insulin sensitivity, blood pressure, endothelial function, cardiorespiratory fitness, skeletal muscle metabolism, autonomic regulation, and numerous other aspects of health. It doesn't need to target one isolated molecular pathway to produce meaningful benefits.
Now consider inadequate sleep and stress. Poor sleep can adversely influence blood pressure, glucose regulation, appetite, sympathetic nervous system activity, and inflammatory signaling. Chronic psychological stress can influence neuroendocrine activity, autonomic function, blood pressure, sleep, and health behaviors. And social isolation can influence psychological well-being, stress physiology, and the behaviors that help determine long-term health.
Are you noticing a pattern here?
These foundational influences on health can affect many biological systems simultaneously. They aren't just a collection of independent cardiovascular risk factors. They help shape the entire physiological environment in which cardiovascular disease either develops or is prevented. Is it any wonder then that, for example, studies like that from Dr Dean Ornish, that implemented a healthy eating pattern, stress reduction, group therapy, smoking cessation and exercise, but no medications still appeared to lead to such impressive reductions in cardiovascular events compared to the control group that just followed normal medical advice? It was a small study with limitations, but its results would be hard to explain otherwise.
Lifestyle medicine deserves a much more prominent role.
The American College of Lifestyle Medicine identifies six pillars of lifestyle medicine:
Whole-food, plant-predominant nutrition
Regular physical activity
Restorative sleep
Stress management
Positive social connections
Avoidance of risky substances
Look at these six pillars through the lens of everything we've just discussed. Each can influence multiple aspects of physiology and behavior. And importantly, they interact with one another. Regular exercise can improve sleep. Better sleep can improve appetite regulation, energy, and the ability to exercise. Improved nutrition can support metabolic health and healthy body weight. Stress management can improve sleep and help people maintain healthier behaviors. Strong social connections can support adherence to positive lifestyle changes.
These are not six isolated interventions. They represent an interconnected approach to improving the conditions that influence health and disease. And VERY IMPORTANTLY, this can even be further improved upon. My approach, which I call the F.L.O.W. Method, and teach to people in my group coaching program adds two additional components to these 6 steps (therapeutics & integrative lipid management, and circadian health) to get an even more potent, wide ranging physiological impact on your body, and thus even more potent overall effects on cardiovascular health.
This brings me to what I think may be one of the most important questions in preventive cardiology:
What if the greatest opportunities for cardiovascular risk reduction are being missed because we continue to place so much emphasis on treating downstream manifestations of disease rather than putting even more emphasis on the upstream factors that contribute to them?
Again, as an integrative doctor, I don't mean that medications should be abandoned. I just mean that perhaps mainstream medicine has gotten the hierarchy wrong.
We should also acknowledge an important limitation of this argument.
It would be scientifically irresponsible to suggest that HORIZON and ZEUS failed simply because they didn't address the root causes of cardiovascular disease. We don't know that. Lp(a), for example, is predominantly genetically determined. Someone can have an exceptionally healthy lifestyle and still have markedly elevated Lp(a).
And the failure of one Lp(a)-lowering or anti-inflammatory drug trial doesn't establish that these are unimportant factors or that lowering either earlier, longer, or through a different intervention cannot reduce cardiovascular events.
We also, again, have excellent evidence that some targeted interventions work extraordinarily well. LDL/ApoB lowering is one of the clearest examples. The benefits of reducing exposure to atherogenic lipoproteins are supported by multiple independent lines of evidence, including genetics, epidemiology, imaging, and randomized clinical trials. And the earlier and longer we reduce excessive exposure, the greater the potential cumulative benefit.
So this is not an argument against identifying and treating specific causal mechanisms. It's an argument against assuming that doing so is a sufficient or possibly even necessary strategy for comprehensive cardiovascular prevention if we instead take the approach I am describing here.
Treating a causal mechanism and addressing the broader conditions that contribute to disease are not competing approaches. They should be complementary.
There's also a major problem with how we generate medical evidence.
Think about how much research funding goes toward identifying individual molecular targets and developing drugs that modify them. We then conduct large randomized trials to determine whether those interventions reduce clinical events. This approach has generated enormous knowledge about this disease and progress in treating it.
But also consider the challenges involved in conducting similarly rigorous trials of comprehensive lifestyle intervention. How do you blind participants to an intensive dietary intervention? How do you maintain meaningful differences in exercise, nutrition, sleep, and stress management between groups for five or ten years? How do you account for adherence, changes in medications, differences in motivation, and the enormous variation in how people respond to lifestyle interventions? And who funds these massive trials when there isn't a patentable pharmaceutical product at the end?
These challenges don't mean lifestyle interventions should be exempt from rigorous scientific evaluation. Quite the opposite actually.
Trial failures like ZEUS and HORIZON help suggest we need better trials, more funding, and more sophisticated ways to evaluate comprehensive nutrition and lifestyle interventions.
Unfortunately, the amount of research funding directed toward an intervention is not necessarily proportional to its potential importance for human health.
Our medical evidence base may be shaped as much by what is commercially practical to study as by what is biologically most important to treat. This is hopefully as concerning for you as it is for me.
What if we're asking the wrong question?
When a drug trial fails, the discussion often revolves around whether we targeted the wrong pathway, selected the wrong patients, intervened too late, or used an insufficiently effective drug, and technically, those are legitimate questions.
But I would like to see another question become much more prominent.
What would happen if we addressed as many of the major upstream drivers of cardiovascular disease as possible, simultaneously and intensively, and then used targeted therapies to manage the REMAINING risk?
Imagine a comprehensive prevention strategy that includes the following:
A predominantly or completely whole-food, plant-based dietary pattern designed to improve cardiometabolic health and reduce atherogenic lipoprotein exposure.
Regular physical activity, including aerobic exercise and resistance training.
Achieving and maintaining a healthy body composition.
Restorative sleep, with appropriate identification and treatment of sleep disorders.
Fasting, and time restricted eating done in ways proven to further aid metabolic health
Meaningful stress management.
Smoking cessation and avoidance of other harmful exposures.
Strong social support and sustainable behavioral changes.
And then, layered onto that foundation, when warranted for specific individuals, we added other individualized medical interventions guided by a thorough assessment of cardiovascular risk and the actual presence and progression of atherosclerosis like:
Targeted use of proven nutritional therapeutics.
Appropriately prescribed medications with a proven track record.
In this strategy, rather than treating lifestyle as something we briefly mention before discussing medications, we would make it a central and initial component of the treatment strategy. And importantly, we would evaluate the results. Not just whether a particular biomarker improved, but whether patients experienced less atherosclerotic disease progression, fewer cardiovascular events, and better long-term health.
That is the kind of comprehensive prevention model I use and that I believe deserves much more attention.
The most important distinction: reducing risk factors versus creating health.
There's one final thought I want to emphasize. In conventional cardiovascular prevention, we often talk about managing risk factors.
We manage cholesterol.
We manage blood pressure.
We manage blood sugar.
We manage inflammation.
And there's nothing inherently wrong with that. But perhaps it reflects a broader limitation in how we think about prevention. Because improving someone's nutrition, fitness, sleep, stress resilience, and metabolic health isn't just about reducing a collection of laboratory abnormalities. It's about improving the function of the organism as a whole.
My takeaway from HORIZON, ZEUS, and SELECT
I don't believe these trials prove that comprehensive lifestyle intervention is superior to targeted pharmaceutical therapy. They can't. Nor do they prove that obesity or metabolic dysfunction explains why one trial succeeded and the others failed. The populations, interventions, mechanisms, and trial designs differ in important ways. But taken together, they should serve as reminder that we also need to ask broader more foundational questions about the nature of cardiovascular risk and how best to reduce it.
We should continue studying Lp(a).
We should continue investigating inflammatory pathways.
We should continue developing better medications.
And we should continue using the treatments that have already demonstrated meaningful clinical benefits.
But we should also devote at least as much intellectual energy, clinical attention, and research funding to understanding what happens when we comprehensively improve the foundational determinants of health. Because poor nutrition, smoking, physical inactivity, inadequate sleep, chronic stress, social disconnection and other factors for drugs are not the answer, don't necessarily create disease through one isolated mechanism. They can influence numerous interconnected pathways, often over decades. And addressing them may offer opportunities for broad improvements that single-target interventions simply cannot fully replicate.
Our goal should be to make the person healthier, reduce their lifetime burden of disease, and help them live longer, better lives.
And that requires seeing the forest, not just the trees, but also remembering the how far the roots of a tree can extend.
PLEASE NOTE: IF THIS TYPE OF THINKING INTERESTS YOU, BE SURE SURE TO CHECK MY UPCOMING ONLINE GROUP COURSES:
December 2nd for laypeople: The F.L.O.W Method for Heart Attack and Stroke Prevention
January 20th for health practitioners: Atherosclerosis Prevention and Treatment for the Busy Clinician
Dr. Daniel Chong, ND, is a naturopathic physician with more than 25 years of clinical experience and advanced training in lipidology, cardiometabolic medicine, and cardiovascular disease risk assessment and prevention. His work emphasizes comprehensive, evidence-informed approaches to preventing heart attacks and strokes.




